Literature DB >> 6721674

Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.

H Y Meltzer, T Kolakowska, V S Fang, L Fogg, A Robertson, R Lewine, M Strahilevitz, D Busch.   

Abstract

The responses of serum prolactin (PRL) and growth hormone (GH) to the dopamine agonist apomorphine hydrochloride (0.75 mg subcutaneously) were studied in a large group of unmedicated hospitalized patients with functional psychoses. There were no differences in the GH response in various diagnostic groups. The PRL response was greater in patients with affective disorders. The GH response was inversely related to total duration of illness in the entire sample of patients, but this correlation was independent of age effect only in the group of patients with major depression. In schizophrenics, the effect of the two factors, age and duration of the illness, could not be separated. The apomorphine-induced GH response was significantly correlated with psychosis ratings and negative symptom scale scores. The apomorphine-induced PRL suppression correlated significantly with various measures of depression across diagnostic groups.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721674     DOI: 10.1001/archpsyc.1984.01790160098013

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  13 in total

1.  Treatment refractory schizophrenia.

Authors:  J P Lindenmayer
Journal:  Psychiatr Q       Date:  2000

2.  Reduced growth hormone response to apomorphine in schizophrenic patients with poor premorbid social functioning.

Authors:  K L Malas; D P van Kammen; E A de Fraites; G M Brown; P W Gold
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

3.  Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses.

Authors:  K I Melkersson; A L Hulting; A J Rane
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

4.  Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia.

Authors:  Byron K Y Bitanihirwe; Daria Peleg-Raibstein; Forouhar Mouttet; Joram Feldon; Urs Meyer
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

5.  Evidence for prolonged recovery of dopaminergic transmission after detoxification in alcoholics with poor treatment outcome.

Authors:  A Heinz; B Lichtenberg-Kraag; S S Baum; K Graf; F Kruger; M Dettling; H Rommelspacher
Journal:  J Neural Transm Gen Sect       Date:  1995

6.  Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients.

Authors:  F Duval; M C Mokrani; J P Macher; M A Crocq; J O Castro; P Bailey; X Lataste
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia.

Authors:  P C Fletcher; C D Frith; P M Grasby; K J Friston; R J Dolan
Journal:  J Neurosci       Date:  1996-11-01       Impact factor: 6.167

Review 8.  Dopamine and depression.

Authors:  A S Brown; S Gershon
Journal:  J Neural Transm Gen Sect       Date:  1993

9.  Responses of prolactin and growth hormone to L-tryptophan infusion: effects in normal subjects and schizophrenic patients receiving neuroleptics.

Authors:  P J Cowen; H Gadhvi; B Gosden; T Kolakowska
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 10.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.